Agorastos Theodoros, Chatzistamatiou Kimon, Zafrakas Menelaos, Siamanta Vagia, Katsamagkas Taxiarchis, Constantinidis Theodoros C, Lampropoulos Alexandros F
a4th Department of Obstetrics and Gynecology b1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki cSchool of Health and Medical Care, Alexander Technological Educational Institute of Thessaloniki, Kentriki Makedonia dLaboratory of Hygiene, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Eur J Cancer Prev. 2014 Sep;23(5):425-31. doi: 10.1097/CEJ.0000000000000060.
The objective of this study was to assess the overall prevalence of the human papilloma virus (HPV) infection and distribution of high-risk HPV (hrHPV) types in Greece and evaluate the participation of women in primary and secondary cervical cancer prevention. This was a prospective, cross-sectional study carried out between October 2005 and January 2011 in Greece; 5379 women filled out the study questionnaire anonymously. 5107 women underwent cervical HPV-DNA testing, either by Hybrid Capture 2, followed by restriction fragment length polymorphism-PCR, or by the Abbott Real-Time High-Risk HPV test. Overall, 5.8% (295/5107) of women were positive for hrHPV infection. The most common hrHPV type was HPV-16 (24.8% among infected women; 1.4% overall), followed by HPV types 31, 35, 53, 18, 51, 56, 58, 52, 39, 66, 45, 33, 59, and 68. In respect to primary prevention of cervical cancer, acceptance of anti-HPV vaccination appeared to decrease over time (from 85-89.9% annually during 2005-2008 to 64.4-60.5% during 2009-2010, P<0.001). In respect to secondary prevention, only 30.3% of women had regular (annually for more than 5 years) Pap smears; regular gynecologic examinations, Papanicolaou testing, and knowledge of HPV were all associated with various demographic parameters (age, education, place of residence, occupation, and income). The prevalence of hrHPV infection in Greece is similar to that in other European countries; the most common type is HPV-16. The initially relatively high acceptance of HPV vaccination decreased after licensing of the vaccine. Demographic parameters appear to influence participation in cervical cancer screening.
本研究的目的是评估希腊人乳头瘤病毒（HPV）感染的总体患病率和高危型HPV（hrHPV）类型的分布情况，并评估女性在宫颈癌一级和二级预防中的参与度。这是一项于2005年10月至2011年1月在希腊开展的前瞻性横断面研究；5379名女性匿名填写了研究问卷。5107名女性接受了宫颈HPV-DNA检测，检测方法要么是采用杂交捕获2法，随后进行限制性片段长度多态性聚合酶链反应，要么是采用雅培实时高危型HPV检测。总体而言，5.8%（295/5107）的女性hrHPV感染呈阳性。最常见的hrHPV类型是HPV-16（在感染女性中占24.8%；总体占1.4%），其次是HPV-31、35、53、18、51、56、58、52、39、66、45、33、59和68型。关于宫颈癌的一级预防，抗HPV疫苗接种的接受度似乎随时间下降（从2005 - 2008年期间的每年85 - 89.9%降至2009 - 2010年期间的64.4 - 60.5%，P<0.001）。关于二级预防，只有30.3%的女性进行定期（每年一次，持续超过5年）巴氏涂片检查；定期妇科检查、巴氏试验以及对HPV的了解均与各种人口统计学参数（年龄、教育程度、居住地点、职业和收入）相关。希腊hrHPV感染的患病率与其他欧洲国家相似；最常见的类型是HPV-16。疫苗获批后，HPV疫苗接种最初相对较高的接受度有所下降。人口统计学参数似乎会影响宫颈癌筛查的参与度。
